Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George D Maynard

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Expert Opinion on Investigational Drugs|July 28, 2012
Targeting memory processes with drugs to prevent or cure PTSDChristopher K Cain, George D Maynard, John H Kehne
Psychopharmacology|November 25, 2010
Emergence of anti-conflict effects of zolpidem in rhesus monkeys following extended post-injection intervalsJames K Rowlett, John H Kehne, Ken J Sprenger, et al.
Plos One|September 17, 2013
The newly developed CRF1-receptor antagonists, NGD 98-2 and NGD 9002, suppress acute stress-induced stimulation of colonic motor function and visceral hypersensitivity in ratsMulugeta Million, Jing-Fang Zhao, Andrew Luckey, et al.
Brain : a Journal of Neurology|May 7, 2020
Nogo receptor decoy promotes recovery and corticospinal growth in non-human primate spinal cord injuryXingxing Wang, Tianna Zhou, George D Maynard, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 30, 2008
Identification and characterization of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a novel, orally bioavailable C5a receptor inverse agonistRobbin M Brodbeck, Daniel N Cortright, Andrzej P Kieltyka, et al.
Journal of Medicinal Chemistry|May 31, 2011
Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonistKevin J Hodgetts, Ping Ge, Taeyoung Yoon, et al.
Bioorganic & Medicinal Chemistry Letters|May 2, 2008
Aminopyrazine CB1 receptor inverse agonistsDavid J Wustrow, George D Maynard, Jun Yuan, et al.
Cell Reports|January 4, 2019
Rescue of Transgenic Alzheimer's Pathophysiology by Polymeric Cellular Prion Protein AntagonistsErik C Gunther, Levi M Smith, Mikhail A Kostylev, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Expert Opinion on Investigational Drugs|July 28, 2012
Targeting memory processes with drugs to prevent or cure PTSDChristopher K Cain, George D Maynard, John H Kehne
Psychopharmacology|November 25, 2010
Emergence of anti-conflict effects of zolpidem in rhesus monkeys following extended post-injection intervalsJames K Rowlett, John H Kehne, Ken J Sprenger, et al.
Plos One|September 17, 2013
The newly developed CRF1-receptor antagonists, NGD 98-2 and NGD 9002, suppress acute stress-induced stimulation of colonic motor function and visceral hypersensitivity in ratsMulugeta Million, Jing-Fang Zhao, Andrew Luckey, et al.
Brain : a Journal of Neurology|May 7, 2020
Nogo receptor decoy promotes recovery and corticospinal growth in non-human primate spinal cord injuryXingxing Wang, Tianna Zhou, George D Maynard, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 30, 2008
Identification and characterization of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a novel, orally bioavailable C5a receptor inverse agonistRobbin M Brodbeck, Daniel N Cortright, Andrzej P Kieltyka, et al.
Journal of Medicinal Chemistry|May 31, 2011
Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonistKevin J Hodgetts, Ping Ge, Taeyoung Yoon, et al.
Bioorganic & Medicinal Chemistry Letters|May 2, 2008
Aminopyrazine CB1 receptor inverse agonistsDavid J Wustrow, George D Maynard, Jun Yuan, et al.
Cell Reports|January 4, 2019
Rescue of Transgenic Alzheimer's Pathophysiology by Polymeric Cellular Prion Protein AntagonistsErik C Gunther, Levi M Smith, Mikhail A Kostylev, et al.
Pageof 1